Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 85
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Mifepristone improves glycemic control in type 2 diabetes
Última actualización 12 de septiembre de 2026
Key finding
At 24 weeks, the least squares mean (LSM) difference from placebo in HbA1c was -1.32% (95% CI -1.81 to -0.83; P < 0.001).
This study evaluated the effects of mifepristone on glycemic control in type 2 diabetes patients, finding significant improvements in HbA1c levels.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Extended (5–20+ y)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of mifepristone on glycemic control in type 2 diabetes patients, finding significant improvements in HbA1c levels.
Clinical relevance
These findings suggest that mifepristone could be a valuable treatment option for managing type 2 diabetes, particularly for patients struggling with glycemic control and weight management. Improved HbA1c levels can lead to better long-term health outcomes and reduced risk of diabetes-related complications.
Keep in mind
The study did not assess long-term effects beyond 24 weeks. Adverse events were reported but not quantified in detail. Sample size and demographic diversity may limit generalizability.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Ralph AD, Vivian F, Vanita RA, et al. Cortisol-Directed Medical Therapy with Mifepristone Improves Glycemic Control in Type 2 Diabetes. Diabetes Care. 2025;48(12):2036-2044. doi:10.2337/dc25-1055
Efectos Principales
Mifepristone reduced HbA1c by -1.32% (P < 0.001).
Participants lost an average of -5.12 kg in body weight.
Waist circumference decreased by -5.1 cm.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Mifepristone and Body weight, Diastolic blood pressure, Fasting Plasma Glucose (FPG), and 6 more.
This study contributes evidence to
Primary intervention
Mifepristone
Primary outcomes
- Body weight
- Diastolic blood pressure
- Fasting Plasma Glucose (FPG)
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
9
Evidence pairs
9
Relationships
6
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 72
6
Related topics
9
Evidence pairs
2149
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 9 evidence relationships
- Includes primary outcome data
- Linked to 6 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
Blood Pressure
matched_outcome
Evidencia relacionada
Tema de evidencia
Weight Loss
Guardar evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Diastolic blood pressure
Mifepristone → Diastolic blood pressure
Mifepristone → Diastolic blood pressure
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerFasting Plasma Glucose (FPG)
Mifepristone → Fasting Plasma Glucose (FPG)
Mifepristone → Fasting Plasma Glucose (FPG)
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 100
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 85
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence TrackerEvidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
La Evidencia Sugiere
- HbA1c decreased by -1.32% in the mifepristone group.
- Body weight reduced by -5.12 kg compared to placebo.
- Waist circumference decreased by -5.1 cm.
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Patients seeking improved glycemic control.
Tener en Cuenta
- Results are based on a 24-week study duration.
- Adverse events were common, including hypokalemia and fatigue.
- Further research is needed to confirm long-term safety and efficacy.
Entre Líneas
- The study did not assess long-term effects beyond 24 weeks.
- Adverse events were reported but not quantified in detail.
- Sample size and demographic diversity may limit generalizability.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Mifepristone and Body Weight, Mifepristone and Blood Pressure.
Relaciones de evidencia relacionadas
Explore in Evidence ExplorerThis study contributes to the evidence on the following intervention-outcome relationships.
Behavioral & Lifestyle
Mifepristone → Body Weight
Behavioral & Lifestyle
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 85
- Very Positive
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceBehavioral & Lifestyle
Mifepristone → Blood Pressure
Behavioral & Lifestyle
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceBehavioral & Lifestyle
Mifepristone → Fasting Glucose
Behavioral & Lifestyle
Evidence Intelligence™
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ImpactScore™
- 50
- Neutral
- ConsistencyScore™
- unclear
- Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
1 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Body Weight Evidence Hub
All studies measuring Body Weight
1 studies
outcome_hubMeasures Body Weight as a key outcome.
Fasting Glucose Evidence Hub
All studies measuring Fasting Glucose
1 studies
outcome_hubMeasures Fasting Glucose as a key outcome.
Mifepristone Evidence Hub
All studies on Mifepristone
1 studies
intervention_hubContributes to Mifepristone evidence base.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en Evidence Explorer
Jump to pre-filtered views in Evidence Explorer.
All studies on Mifepristone and Body weight
Intervention: MifepristoneOutcome: Body weight
1 results
All studies on Mifepristone and Diastolic blood pressure
Intervention: MifepristoneOutcome: Diastolic blood pressure
1 results
All studies on Mifepristone
Intervention: Mifepristone
1 results
All studies measuring Body weight
Outcome: Body weight
1 results
All studies measuring Diastolic blood pressure
Outcome: Diastolic blood pressure
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does Mifepristone affect body weight?
Emerging Evidence
Mifepristone appears to affect body weight.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Mifepristone lower HbA1c?
Emerging Evidence
Mifepristone appears to lower HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Mifepristone affect waist circumference?
Emerging Evidence
Mifepristone appears to affect waist circumference.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Waist circumference
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Does Mifepristone improve diastolic blood pressure?
Emerging Evidence
Current evidence does not show a clear benefit of Mifepristone for diastolic blood pressure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
- 1
Diastolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
- Only one supporting study is available.
Next steps
Continue your research
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in Evidence Explorer
Open broader Evidence Explorer views for this relationship.
Related research
Read related research summaries.
Structured exercise improves metabolic health in prediabetic adultsTirzepatide significantly reduces body weight in Japanese adults with T2DHigh-protein diet may reduce cardiometabolic risks in diabetes patientsInsulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Exercise Improves Serum Albumin Levels in Women with Type 2 Diabetes
Sin anuncios. Sin rastreo.
Centrada en la evidencia, no en la publicidad.
Segura y privada
Tus datos siempre están protegidos.
Siempre al día
Se agregan nuevos estudios todos los días.